NGeneBio Co., Ltd. (KOSDAQ:354200)
South Korea · Delayed Price · Currency is KRW 992.00
-15.00 (-1.49%)
At close: Jun 5, 2026
NGeneBio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Other Revenue | - | -0 | - | 0 | - | - |
| 31,200 | 21,240 | 5,611 | 4,351 | 11,018 | 7,163 | |
Revenue Growth (YoY) | 363.66% | 278.54% | 28.96% | -60.51% | 53.81% | - |
Cost of Revenue | 26,958 | 17,464 | 3,562 | 4,505 | 6,889 | 4,773 |
Gross Profit | 4,242 | 3,776 | 2,049 | -153.65 | 4,128 | 2,390 |
Selling, General & Admin | 9,113 | 8,816 | 10,540 | 7,834 | 7,389 | 6,011 |
Research & Development | 1,498 | 1,662 | 2,732 | 4,505 | 4,584 | 4,456 |
Amortization of Goodwill & Intangibles | 284.15 | 278.62 | 238.83 | 185.36 | 178 | 147.24 |
Other Operating Expenses | 371.03 | 481.55 | 496.48 | 58.85 | 69.25 | 148.6 |
Operating Expenses | 12,042 | 12,052 | 14,641 | 13,271 | 12,728 | 11,122 |
Operating Income | -7,800 | -8,276 | -12,592 | -13,425 | -8,599 | -8,732 |
Interest Expense | -2,621 | -1,637 | -1,713 | -1,781 | -665.44 | -155.25 |
Interest & Investment Income | 88.59 | 82.25 | 224.34 | 991.59 | 852.58 | 261.76 |
Earnings From Equity Investments | 314.19 | - | - | - | - | 199.05 |
Currency Exchange Gain (Loss) | 164.26 | -43.79 | 223.79 | 23.95 | 84.28 | 0.71 |
Other Non Operating Income (Expenses) | -2,286 | -443.71 | 3,858 | 1,659 | -1,332 | 28.42 |
EBT Excluding Unusual Items | -12,141 | -10,318 | -9,999 | -12,531 | -9,660 | -8,397 |
Gain (Loss) on Sale of Investments | 8,141 | 8,158 | -855.76 | -526.16 | -144.52 | 1.77 |
Gain (Loss) on Sale of Assets | -36.84 | -22.32 | -14.8 | -20.85 | -0.99 | -11.15 |
Asset Writedown | -2,026 | -2,012 | -34.04 | -97.62 | -34.1 | -24.56 |
Other Unusual Items | -251.47 | -124.42 | -145.5 | - | - | - |
Pretax Income | -6,314 | -4,319 | -11,049 | -13,175 | -9,839 | -8,431 |
Income Tax Expense | -965.45 | -965.45 | -116.89 | -315.69 | - | - |
Earnings From Continuing Operations | -5,348 | -3,353 | -10,932 | -12,860 | -9,839 | -8,431 |
Earnings From Discontinued Operations | -2,585 | -3,404 | -3,358 | - | - | - |
Net Income to Company | -7,934 | -6,757 | -14,290 | -12,860 | -9,839 | -8,431 |
Minority Interest in Earnings | 934.1 | 1,215 | 1,315 | 90.92 | 53.96 | - |
Net Income | -7,000 | -5,542 | -12,976 | -12,769 | -9,785 | -8,431 |
Net Income to Common | -7,000 | -5,542 | -12,976 | -12,769 | -9,785 | -8,431 |
Shares Outstanding (Basic) | 24 | 22 | 14 | 13 | 12 | 12 |
Shares Outstanding (Diluted) | 24 | 22 | 14 | 13 | 12 | 12 |
Shares Change (YoY) | 51.10% | 58.58% | 11.80% | 1.66% | 0.89% | - |
EPS (Basic) | -291.13 | -246.46 | -915.00 | -1006.63 | -784.21 | -681.70 |
EPS (Diluted) | -291.13 | -246.46 | -915.00 | -1007.00 | -784.21 | -682.00 |
Free Cash Flow | -31,821 | -34,334 | -12,566 | -9,553 | -8,849 | -10,546 |
Free Cash Flow Per Share | -1323.49 | -1526.80 | -886.12 | -753.13 | -709.15 | -852.68 |
Gross Margin | 13.60% | 17.78% | 36.52% | -3.53% | 37.47% | 33.36% |
Operating Margin | -25.00% | -38.96% | -224.42% | -308.56% | -78.05% | -121.90% |
Profit Margin | -22.43% | -26.09% | -231.25% | -293.48% | -88.82% | -117.70% |
Free Cash Flow Margin | -101.99% | -161.65% | -223.95% | -219.57% | -80.32% | -147.22% |
EBITDA | -6,049 | -6,049 | -9,660 | -12,081 | -7,325 | -7,702 |
EBITDA Margin | -19.39% | -28.48% | -172.16% | -277.67% | -66.49% | -107.52% |
D&A For EBITDA | 1,752 | 2,227 | 2,932 | 1,344 | 1,274 | 1,030 |
EBIT | -7,800 | -8,276 | -12,592 | -13,425 | -8,599 | -8,732 |
EBIT Margin | -25.00% | -38.96% | -224.42% | - | -78.05% | -121.90% |
Advertising Expenses | - | 381.41 | 598.68 | 348.42 | 336.73 | 287.33 |